Portland State chemists report T111 cleared malaria stages in lab and animal tests, suggesting a single‑encounter cure could be possible.

Arizona will lead NNME Southwest, coordinating training and employer partners across five states to tackle a projected shortfall in chip industry workers.

VectorBuilder plans a $50M, 35,000‑sq‑ft R&D lab on Chicago’s South Side, targeting a 2027 opening and expanding the city’s CDMO capacity.

Scottsdale will use Motorola HYPER to handle routine non-emergency police calls, aiming to cut hold times while keeping human dispatchers focused on 911. The city says training and a phased rollout are already underway.

Gilead’s Hepcludex won FDA accelerated approval on May 22, 2026 — the first U.S. therapy for chronic hepatitis D — as Mirum and Vir push rival candidates toward late‑stage results.

Golden-based Lunar Outpost says its Pegasus rover was chosen by NASA to help explore and prepare the lunar south pole. The move pairs the startup with big industry partners.

Interim data show a single infusion of a PCSK9 base editor sharply lowered LDL in an early trial, while Cleveland researchers link low nitric oxide to altered gene splicing in Alzheimer’s. Clinicians warned that supplements aren’t regulated like drugs and can carry risks.

Dropbox founder Drew Houston promoted Ashraf Alkarmi to co‑CEO and will transition to executive chairman as the company leans into AI and product work.

The Supreme Court declined to block Vermont’s consumer‑protection suit accusing Instagram of engineering features that addict teens, allowing the case to proceed. The decision follows recent state court setbacks for Meta.

Oklo says it has been picked by the DOE for talks to turn Cold War plutonium into reactor fuel while critics warn of serious proliferation and safety concerns. The company will partner with newcleo and says strict safeguards would apply.

State records show Meta will cut 1,395 Washington jobs, with Seattle-area offices and remote staff affected. Notices list July 22 as the separation date.

After a failed flu trial, Marianne De Backer closed labs, cut staff and struck licensing deals that refocused San Francisco’s Vir on hepatitis and cancer. The result is a leaner company with big‑pharma partners.

UH Cancer Center researcher Michele Carbone won the 2026 Szent‑Györgyi Prize for work linking inherited BAP1 mutations to mesothelioma and spurring life‑saving interventions.